SBWire

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII. Severe hemophilia occurs in about 60% of cases where the deficiency of Factor VIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene.

Braincure Biotech (ISIN:TW0001327872) has recently appointed Chen D. Gou will become Chairman of the Company's Board of Directors, effective immediately. The appointment follows the decision by Tsao T. Wenjung, 65, the Company's former Chairman, to retire from his position. Mr. Wenjung will retire from the Board at the Company's Annual Shareholder Meeting.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced it has awarded a $250.000 Transformational Grant in Science Education to the Biotechnology Center to support the expansion of the Center's educational training facility for science teachers. The grant is part of the Genocore Biotech Foundation's new Transformational Grants in Science Education initiative.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody, today announced that the company has appointed HonWen Long, M.D., to its Scientific Advisory Board. Dr. Wen Long is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders. Currently Dr. Wen Long is Professor of Psychiatry, Neurology & Medicine.

Braincure Biotech (ISIN:TW0001327872) has recently appointed Mr. Lee Yung Lung as the Chief Operating Officer (COO) of the company.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced an agreement for the further development of a novel, oral small molecule inhibitor of Vascular Protein 1, a cell molecule that may be effective in the treatment of inflammatory diseases. The inhibitor is currently in phase II clinical development.

Braincure-Biotech.com (ISIN:TW0001327872) reported that in preclinical studies, injections of the protein Artemin promoted the regeneration of damaged sensory nerve cells and produced virtually complete, long-term restoration of sensory and motor function.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced that they plan to advance the companies' Hemophilia B therapy a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a pharmacokinetic study in severe, previously-treated hemophilia B patients. In addition, the therapy demonstrated a prolonged half-life compared to historical data for existing therapies, supporting advancement of the program.

GlobalData's clinical trial report, "Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" provides an overview of Acute Upper Respiratory Tract Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Upper Respiratory Tract Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024

Q BioMed Inc., a biotechnology acceleration company is pleased to welcome David Laskow-Pooley to the Q Team as VP Scientific & Product Development.

Kitov Pharmaceuticals an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Data from the trial further revealed that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate. Kitov plans to file its New Drug Application (NDA) for marketing approval of KIT-302 with the FDA in the second half of 2016.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions refractory and relapsed Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). The Company has recently submitted an Investigational New Drug (IND) application for Iomab-B with the FDA and is preparing for a pivotal, Phase 3 trial.

PT-141 is considered as the ever first in the novel class of therapies (also known as melanocortin agonists) which also work via a system of action involving the central nervous system and not directly on the vascular system. What is notable about the use of PT-141 is that it offers an extensively safety and effective benefits over the readily available products like Viagra, Cialis,and Levitra.

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA's acceptance of the IND filing, Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55.

CEL-SCI Corporation announces that it has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy. The patent, number EP 1 753 452 B, is entitled: A METHOD FOR ALTERING THE CD4/CD8 RATIO AND THE MONONUCLEAR CELLULAR INFILTRATE INTO A TUMOR.

Tim joins Ignite Data after a varied and successful executive career, most recently as CEO of King's College Hospital NHS Foundation Trust. Prior to joining the NHS Tim worked first for Shell, then in a series of increasingly complex roles in BT, culminating in him being responsible for all BT's big contracts in the UK, including those with the NHS and with UK based pharmaceuticals.

An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries. The recently launched Phos-Cat4 has been specially designed to be just as effective as the rest of the PhosphonicS acid catalyst range but offer even more stability.

Q BioMed Inc., a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Dr. Xin Du, Ph.D., to the position of Executive Director, Regulatory Affairs and Dr. Sri Srivastava, Ph.D., PMP, to the position of Associate Director of Project Management. Dr. Srivastava will have operational responsibilities for Actinium's Actimab-A program including the planned Phase 2 trial, planning and process optimization, management of external vendors and the coordination of all clinical trial related matters. Dr. Du will be responsible for managing Actinium's regulatory submissions, CMC efforts, interacting with regulatory agencies and developing the Company's regulatory strategy as pertains to both Iomab-B, Actimab-A and all future programs. Both hires are especially timely given the planned transformation of Actinium into a later stage product development company in 2016.

GlobalData's clinical trial report, "Renal Stones/Calculi Global Clinical Trials Review, H2, 2015" provides an overview of Renal Stones/Calculi clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Stones/Calculi. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that subsequent to its pre-IND (Investigative New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its Iomab-B drug candidate, the Company is finalizing the IND filing for submission to the FDA to support the start of the Phase 3 clinical study.

Creative Biolabs is glad to announce a new series of stable cell lines services.

Nowadays, an increasing number of people who are suffering from medical conditions, such as gallbladder problems, are resorting to various natural alternatives. Ailments such as gallstones can be troublesome, and this is why many sufferers use remedies that can potentially provide them with the solution they are looking for.

"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD